US 12,171,793 B2
Method of activating lactic acid bacteria
Staffan Stromberg, Nacka (SE); Eamonn Connolly, Lindingo (SE); and Stefan Roos, Uppsala (SE)
Assigned to INFANT BACTERIAL THERAPEUTICS AB, Stockholm (SE)
Appl. No. 15/320,996
Filed by INFANT BACTERIAL THERAPEUTICS AB, Stockholm (SE)
PCT Filed Jan. 14, 2016, PCT No. PCT/EP2016/050694
§ 371(c)(1), (2) Date Dec. 21, 2016,
PCT Pub. No. WO2016/113363, PCT Pub. Date Jul. 21, 2016.
Claims priority of provisional application 62/103,201, filed on Jan. 14, 2015.
Prior Publication US 2017/0304376 A1, Oct. 26, 2017
Int. Cl. A61K 35/747 (2015.01); A23L 33/135 (2016.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 9/16 (2006.01); A61K 9/19 (2006.01); A61K 31/194 (2006.01); A61K 35/744 (2015.01); A61K 47/12 (2006.01); C12N 1/20 (2006.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/10 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/19 (2013.01); A61K 31/194 (2013.01); A61K 35/744 (2013.01); A61K 47/12 (2013.01); C12N 1/20 (2013.01)] 19 Claims
 
1. A method of treating a neonate, a premature infant, or an infant having a condition benefiting from the administration of reconstituted live Lactobacillus reuteri with faster activation following dormancy, the method comprising:
administering to the neonate, premature infant, or infant a composition comprising a therapeutically effective amount of the reconstituted live L. reuteri in the presence of citrate, wherein the reconstituted live L. reuteri use the citrate as an electron acceptor and the reconstituted live L. reuteri are prepared from frozen or lyophilized L. reuteri activated by the citrate to result in metabolizing L. reuteri, wherein the citrate is an external electron acceptor, and wherein the citrate is present when the L. reuteri is frozen or lyophilized or the citrate is added to the frozen or lyophilized L. reuteri prior to or during reconstitution,
wherein the reconstituted live L. reuteri in the presence of citrate have a faster activation rate following dormancy compared to the activation rate following dormancy for the same L. reuteri that are reconstituted in the absence of citrate and the faster activation rate is a faster increase in growth over the same time period, thereby treating the condition of the neonate, premature infant, or infant that benefits from the administration of the reconstituted live L. reuteri with faster activation following dormancy.